Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease
Recruiting in Palo Alto (17 mi)
Age: 18 - 65
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Waitlist Available
Sponsor: Banner Health
No Placebo Group
Prior Safety Data
Approved in 3 jurisdictions
Trial Summary
What is the purpose of this trial?To evaluate the magnitude of the humoral immune responses to quadrivalent vs trivalent influenza vaccines in adults between the age of 50 and 64 years with a prior diagnosis of GOLD Stage C and D COPD vs. those patients without COPD.
Eligibility Criteria
Participant Groups
2Treatment groups
Active Control
Group I: COPDActive Control1 Intervention
Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.
Group II: ControlActive Control1 Intervention
Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.
Fluzone is already approved in United States, Canada for the following indications:
🇺🇸 Approved in United States as Fluzone High-Dose for:
- Influenza immunization for persons aged ≥65yrs
🇨🇦 Approved in Canada as Fluzone High-Dose Quadrivalent for:
- Influenza immunization for persons aged ≥65yrs
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
Pulmonary AssociatesPhoenix, AZ
Loading ...
Who is running the clinical trial?
Banner HealthLead Sponsor
Sanofi Pasteur, a Sanofi CompanyIndustry Sponsor